You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Claims for Patent: 6,958,335

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,958,335

Title:	Treatment of gastrointestinal stromal tumors
Abstract:	4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2- ylamino)phenyl]-benzamide of the formula I ##STR1## or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Inventor(s):	Buchdunger; Elisabeth (Neuenburg, DE), Capdeville; Renaud (Riedesheim, FR), Demetri; George Daniel (Brookline, MA), Dimitrijevic; Sasa (Habsheim, FR), Druker; Brian Jay (Portland, OR), Fletcher; Jonathan A. (Brookline, MA), Heinrich; Michael C. (Lake Oswego, OR), Joensuu; Heikki (Helsinki, FI), Silberman; Sandra Leta (Randolph, NJ), Tuveson; David (Berwyn, PA)
Assignee:	Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) Oregon Health & Science University (Portland, OR)
Application Number:	10/415,015
Patent Claims:	1. A method of treating gastrointestinal stromal tumours which comprises administering to a human in need of such treatment a dose, effective against gastrointestinal stromal tumours, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide of the formula I ##STR3## or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 wherein a pharmaceutically acceptable acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -yl-amino)phenyl]-benzamide of the formula I is administered. 3. The method according to claim 1 wherein a methanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide of the formula I is administered. 4. The method according to claim 1 wherein a daily dose of 200 to 600 mg of a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide of the formula I is administered to an adult human. 5. A method for administering to a human subject having gastrointestinal stromal tumours 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyrimidin-3-yl)pyrimidin -2-ylamino)phenyl]-benzamide of the formula I ##STR4## or a pharmaceutically acceptable salt thereof, which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof to the human subject once daily for a period exceeding 3 months. 6. A method according to claim 5 wherein a daily dose of 200 to 600 mg of monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide of the formula I is administered.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.